JITC Publication on the Mechanism of Akes’ Ligufalimab (a CD47 Monoclonal Antibody) Shows Promising Antitumor Efficacy and a Favorable Safety Profile
HONG KONG, December 11, 2022 /PRNewswire/ — Akeso Inc. (9926. HK) (“Akeso”) announced today that the Journal for Immunotherapy of Cancer (JITC), a BMJ oncology journal, has published the mechanism of action of its Ligufalimab (AK117). The title of the article is “Ligufalimab, a novel non-hemagglutination-free anti-CD47 antibody that shows both monotherapy and combination antitumor …